Interfacing Chemical Biology and Drug Discovery

RICT 2021

56th International Conference on Medicinal Chemistry
56èmes Rencontres Internationales de Chimie Thérapeutique

 Virtual Event    July 7-9, 2021

Programme

Indicated times are in CEST timezone.



09:45

Opening Ceremony

Chemical Biology and Target validation

Session Chair introduction

10:00

Expanding the Genetic Code - Chemistry in Living Systems (PL01)

Prof. Kathrin LANG
ETH ZURICH, Zurich, Switzerland

10:30

Ligand-Directed Labeling of Endogenous Proteins in Live Cells (PL02)

Prof. Itaru HAMACHI
KYOTO UNIVERSITY, Kyoto, Japan

11:00

Networking & Exhibition break

11:30

Bioorthogonal Protein Activation in Living Systems (PL03)

Prof. Peng CHEN
PEKING UNIVERSITY, Beijing, China

12:00

Chemical Biology Tools for Enlightening Therapies (IL01)

Prof. Olalla VÁZQUEZ
PHILIPPS-UNIVERSITÄT MARBURG, Marburg, Germany

12:20

End of morning session

13:00

Poster Session
Exhibition

New Modalities in Drug Discovery

Session Chair introduction

15:00

Chemical Targeting of DNA and Histone Methylationto Reprogram Cells in Human Diseases: Challenges and Future Perspectives (PL04)

Dr Paola B. ARIMONDO
INSTITUT PASTEUR - CNRS, Paris, France

15:30

The Second Dimension of the Genetic Code (PL05)

Prof. Thomas CARELL
LUDWIG-MAXIMILIANS-UNIVERSITY, München, Germany

16:00

Networking & Exhibition

16:30

From Simple to Complex in Natural Product Chemistry: Bio-Inspired Strategies to Escape “Flatland” (PL06)

Prof. Erwan POUPON
PARIS-SACLAY UNIVERSITY, Châtenay-Malabry, France

17:00

Taming Random Conjugation: a General Approach for Equimolar Linking of Proteins and Payloads (IL02)

Dr Sergii KOLODYCH
SYNDIVIA, ILLKIRCH, France

17:20

End of afternoon session

Case Studies and Disclosures

Session Chair introduction

10:00

Steroid Sulfatase Inhibition: from Concept to Clinical and Beyond (PL07)

Prof. Barry POTTER
UNIVERSITY OF OXFORD, Oxford, United Kingdom

10:30

Recent Advances in Breast Cancer Treatment: Discovery of SAR439859, a Selective Estrogen Receptor Degrader for the Treatment of Estrogen-Receptor-Positive Breast Cancer (PL08)

Dr Youssef EL AHMAD
SANOFI, Vitry Sur Seine, France

11:00

Networking & Exhibition

11:30

Daridorexant - a Dual Orexin Receptor Antagonist (PL09)

Dr Christoph BOSS
IDORSIA PHARMACEUTICALS LTD, Allschwil, Switzerland

12:00

Anti-Virulence Agent to Treat S. Aureus Infections (IL03)

Dr Alessia MICHELOTTI
BIOVERSYS AG, Basel, Switzerland

12:20

End of morning session

13:00

Poster Session
Exhibition

New Tools for Therapeutic Innovation

Session Chair introduction

15:00

Multi-Target-Directed Ligands to Combat Neurodegenerative Diseases: All-In-One and One-For-All (PL10)

Prof. Maria Laura BOLOGNESI
UNIVERSITY OF BOLOGNA, Bologna, Italy

15:30

Converting Drug Delivery Technologies into Drugs in Unmet Medical Needs (PL11)

Prof. Jean-Christophe LEROUX
ETH ZÜRICH, Zürich, Switzerland

16:00

Networking & Exhibition

Prize Ceremony - Paul Ehrlich Prize

16:30

Paul Ehrlich Prize Ceremony

16:40

Paul Ehrlich Award Lecture - 30 Years of Molecular Glues: Controlling Cell Circuitry in Biology and Medicine (PL12)

Prof. Stuart SCHREIBER
HARVARD UNIVERSITY, Cambridge, United States

17:25

End of afternoon session

Drugging the Undrugable

Session Chair introduction

10:00

Targeting Protein-Protein Interactions in Receptor Complexes (PL13)

Prof. Kristian STROMGAARD
UNIVERSITY OF COPENHAGEN, Copenhagen, Denmark

10:30

Selecting Targets to Harness the Therapeutic Opportunities Afforded by PROTAC-mediated Protein Degradation (PL14)

Dr John HARLING
GLAXOSMITHKLINE, Stevenage, United Kingdom

11:00

Networking & Exhibition

11:30

Proteomimetics as Inhibitors of Transcription Factor Complexes (PL15)

Prof. Tom GROSSMANN
VU UNIVERSITY AMSTERDAM, Amsterdam, The Netherlands

12:00

Drugging KRAS with Medchem 2.0 (PL16)

Dr Darryl MCCONNELL
BOEHRINGER INGELHEIM RCV, Vienna, Austria

12:30

End of morning session

13:00

Poster Session
Exhibition
Nertworking

Success Stories

Session Chair introduction

15:00

Identification of the Potent, Highly Selective and Orally Bioavailable ATR Inhibitor BAY 1895344 (PL17)

Dr Franz VON NUSSBAUM
NUVISAN ICB GMBH, Berlin, Germany

15:30

Biomimetic Chemistry of Human RNAi Therapeutics (PL18)

Dr Mano MANOHARAN
ALNYLAM PHARMACEUTICALS, Cambridge, United States

16:00

Networking & Exhibition

Prize Ceremony - Pierre Fabre Award Lecture

16:30

Pierre Fabre Award Ceremony

16:40

Pierre Fabre Award Lecture - Metal Complexes in Medicinal Chemistry (PL19)

Dr Gilles GASSER
CHIMIE PARISTECH, PSL UNIVERSITY, Paris, France

17:25

End of afternoon session